Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities

Blood

Volumn 120, Issue 19, 2012, Pages 3936-3944

  Tel, Jurjen ^a   Smits, Evelien L ^b   Anguille, Sébastien ^b   Joshi, Rubin N ^a   Figdor, Carl G ^a   De Vries, I Jolanda M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; GRANZYME B; TICK BORNE ENCEPHALITIS VACCINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL DESTRUCTION; UPREGULATION;

EID: 84868608481     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-435941     Document Type: Article

References (50)

1. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol. 2004; 5(12):1219-1226. (Pubitemid 41057736)
2. Dzionek A, Inagaki Y, Okawa K, et al. Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. Hum Immunol. 2002; 63(12):1133-1148. (Pubitemid 36025988)
3. Schreibelt G, Tel J, Sliepen KH, et al. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cellbased anti-cancer immunotherapy. Cancer Immunol Immunother. 2010;59(10):1573-1582.
4. Romagnani C, Della Chiesa M, Kohler S, et al. Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4- T helper cells and CD4- CD25hi T regulatory cells. Eur J Immunol. 2005;35(8):2452-2458. (Pubitemid 41179766)
5. Yoneyama H, Matsuno K, Toda E, et al. Plasmacytoid DCs help lymph node DCs to induce anti- HSV CTLs. J Exp Med. 2005;202(3):425-435. (Pubitemid 41126960)
6. Piccioli D, Sammicheli C, Tavarini S, et al. Human plasmacytoid dendritic cells are unresponsive to bacterial stimulation and require a novel type of cooperation with myeloid dendritic cells for maturation. Blood. 2009;113(18):4232-4239.
7. Schettini J, Mukherjee P. Physiological role of plasmacytoid dendritic cells and their potential use in cancer immunity. Clin Dev Immunol. 2008; 2008:106321.
8. Trinchieri G. Type I interferon: friend or foe? J Exp Med. 2010;207(10):2053-2063.
9. Moseman EA, Liang X, Dawson AJ, et al. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol. 2004;173(7):4433-4442. (Pubitemid 39280673)
10. Wenner CA, Guler ML, Macatonia SE, O'Garra A, Murphy KM. Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development. J Immunol. 1996;156(4):1442-1447.
11. Salio M, Cella M, Vermi W, et al. Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol. 2003;33(4):1052-1062. (Pubitemid 36546693)
12. Vicari AP, Chiodoni C, Vaure C, et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and antiinterleukin 10 receptor antibody. J Exp Med. 2002;196(4):541-549.
13. Conrad C, Meller S, Gilliet M. Plasmacytoid dendritic cells in the skin: To sense or not to sense nucleic acids. Semin Immunol. 2009;21(3):101- 109.
14. Hartmann E, Wollenberg B, Rothenfusser S, et al. Identification and functional analysis of tumorinfiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res. 2003;63(19):6478- 6487.
15. Treilleux I, Blay JY, Bendriss-Vermare N, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res. 2004; 10(22):7466-7474. (Pubitemid 39561754)
16. Wei S, Kryczek I, Zou L, et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 2005; 65(12):5020-5026. (Pubitemid 40827308)
17. Labidi-Galy SI, Sisirak V, Meeus P, et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res. 2011;71(16):5423- 5434.
18. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med. 2007; 204(6):1441-1451. (Pubitemid 46919881)
19. Chan CW, Crafton E, Fan HN, et al. Interferonproducing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med. 2006;12(2):207-213. (Pubitemid 43214747)
20. Taieb J, Chaput N, Menard C, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med. 2006;12(2):214-219. (Pubitemid 43214748)
21. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA. Monocyte-mediated tumoricidal activity via the tumor necrosis factorrelated cytokine, TRAIL. J Exp Med. 1999;189(8): 1343-1354.
22. Papewalis C, Jacobs B, Wuttke M, et al. IFNalpha skews monocytes into CD56+-expressing dendritic cells with potent functional activities in vitro and in vivo. J Immunol. 2008;180(3):1462- 1470.
23. Hardy AW, Graham DR, Shearer GM, Herbeuval JP. HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-alpha. Proc Natl Acad Sci U S A. 2007; 104(44):17453-17458. (Pubitemid 350219859)
24. Stary G, Klein I, Kohlhofer S, et al. Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. Blood. 2009;114(18):3854-3863.
25. Chaperot L, Blum A, Manches O, et al. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol. 2006;176(1):248-255. (Pubitemid 43023269)
26. Matsui T, Connolly JE, Michnevitz M, et al. CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol. 2009;182(11):6815-6823.
27. Bonmort M, Dalod M, Mignot G, Ullrich E, Chaput N, Zitvogel L. Killer dendritic cells: IKDC and the others. Curr Opin Immunol. 2008;20(5): 558-565.
28. Jahrsdörfer B, Vollmer A, Blackwell SE, et al. Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. Blood. 2010;115(6):1156-1165.
29. de Vries IJ, Tel J, Benitez-Ribas D, Torensma R, Figdor CG. Prophylactic vaccines mimic synthetic CpG oligonucleotides in their ability to modulate immune responses. Mol Immunol. 2011;48(6-7): 810-817.
30. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Reviews. 2006; 20(3):123-137. (Pubitemid 43786166)
31. Ou D, Metzger DL, Wang X, Pozzilli P, Tingle AJ. beta-cell antigen-specific CD56(+) NKT cells from type 1 diabetic patients: autoaggressive effector T cells damage human CD56(+) beta cells by HLA-restricted and non-HLA-restricted pathways. Hum Immunol. 2002;63(4):256-270. (Pubitemid 34303696)
32. Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P. Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol. 2000;164(3):1148-1152. (Pubitemid 30067223)
33. Schaft N, Dörrie J, Müller I, et al. A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes. Cancer Immunol Immunother. 2006;55(9):1132-1141. (Pubitemid 43800728)
34. Lion E, Anguille S, Berneman ZN, Smits EL, Van Tendeloo VF. Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC. PLoS One. 2011;6(6): e20952.
35. Tel J, Hato SV, Torensma R, et al. The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues. Cancer Immunol Immunother. 2012;61(7): 1101-1111.
36. Schuurhuis DH, Verdijk P, Schreibelt G, et al. In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients. Cancer Res. 2009; 69(7):2927-2934.
37. de Vries IJ, Lesterhuis WJ, Scharenborg NM, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res. 2003;9(14): 5091-5100. (Pubitemid 37413557)
38. Benitez-Ribas D, Adema GJ, Winkels G, et al. Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after Fc gamma RII-mediated uptake. J Exp Med. 2006;203(7):1629-1635. (Pubitemid 44036266)
39. Gruenbacher G, Gander H, Rahm A, Nussbaumer W, Romani N, Thurnher M. CD56+ human blood dendritic cells effectively promote TH1-type gammadelta T-cell responses. Blood. 2009;114(20):4422-4431.
40. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001;194(6):863- 869.
41. Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999;284(5421): 1835-1837.
42. Cella M, Jarrossay D, Facchetti F, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 1999;5(8):919-923. (Pubitemid 29372419)
43. Nitta T, Yagita H, Sato K, Okumura K. Involvement of CD56 (NKH-1/Leu-19 antigen) as an adhesion molecule in natural killer-target cell interaction. J Exp Med. 1989;170(5):1757-1761. (Pubitemid 19284573)
44. Kalb ML, Glaser A, Stary G, Koszik F, Stingl G. TRAIL+ human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimodand IFN-alpha-mediated antitumor reactivity. J Immunol. 2012;188(4):1583-1591.
45. Kiselyov VV, Berezin V, Maar TE, et al. The first immunoglobulin-like neural cell adhesion molecule (NCAM) domain is involved in doublereciprocal interaction with the second immunoglobulin-like NCAM domain and in heparin binding. J Biol Chem. 1997;272(15):10125- 10134.
46. Gruenbacher G, Gander H, Nussbaumer O, Nussbaumer W, Rahm A, Thurnher M. IL-2 costimulation enables statin-mediated activation of human NK cells, preferentially through a mechanism involving CD56(+) dendritic cells. Cancer Res. 2010;70(23):9611-9620.
47. Nussbaumer O, Gruenbacher G, Gander H, Thurnher M. DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by gamma delta T lymphocytes. Blood. 2011;118(10):2743-2751.
48. Shresta S, Pham CTN, Thomas DA, Graubert TA, Ley TJ. How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol. 1998;10(5):581-587. (Pubitemid 28479192)
49. Diamond MS, Kinder M, Matsushita H, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011;208(10):1989-2003.
50. Drobits B, Holcmann M, Amberg N, et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest. 2012; 122(2):575-585.